Patents Expiring in February 2033
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-001 | Apr 2, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ||||
Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-001 | Apr 2, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-001 | Apr 2, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-002 | Apr 2, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |